Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VoxelLTS:0QDB 95 EV-to-EBIT is 10.73 as of Aug. 17, 2026, which is 7% above its 10-year median of 10.02. GuruFocus rates LTS:0QDB with a GF Score™ of 95/100 and a GF Value™ of zł110.70. The stock has 2 warning signs investors should review. Among 106 Medical Diagnostics & Research companies, Voxel ranks better than 79.25% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Voxel's Enterprise Value is zł1,537.3 Mil.
Voxel's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was zł143.3 Mil. Therefore, Voxel's EV-to-EBIT for today is 10.73.
The historical rank and industry rank for Voxel's EV-to-EBIT or its related term are showing as below:
LTS:0QDB'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.36 Med: 10.02 Max: 22.32
Current: 10.73
During the past 13 years, the highest EV-to-EBIT of Voxel was 22.32. The lowest was 5.36. And the median was 10.02.
LTS:0QDB's EV-to-EBIT is ranked better than 79.25% of 106
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.205
vs LTS:0QDB: 10.73
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Voxel's Enterprise Value for the quarter that ended in Mar. 2026 was zł0.0 Mil.
Voxel's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł143.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voxel EV-to-EBIT Related Terms
Voxel EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Voxel's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Voxel's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voxel EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Voxel's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Voxel's EV-to-EBIT falls into.
Voxel's current Enterprise Value is zł1,537.3 Mil.
Voxel's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł143.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voxel (LTS:0QDB) has a EV-to-EBIT of 10.73 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Voxel and its competitors. This is near median its historical median of 10.02. Over the past decade, Voxel's EV-to-EBIT has ranged from 5.36 to 22.32. According to the industry distribution chart, Voxel ranks #22 out of 106 companies in the Medical Diagnostics & Research industry, placing it in the top 20.8%.
Is Voxel's EV-to-EBIT too high?
Voxel's current EV-to-EBIT of 10.73 is near median its 10-year median of 10.02. Over the past 10 years, this metric has ranged from a low of 5.36 to a high of 22.32. The Medical Diagnostics & Research industry median EV-to-EBIT is 24.21. Voxel's value of 10.73 is 55.7% below this industry median. Based on the distribution chart, Voxel ranks #22 out of 106 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Voxel has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Voxel's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Voxel ranks #22 out of 106 companies for EV-to-EBIT. This places Voxel in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 24.21. Voxel's value of 10.73 is 55.7% below this benchmark. Historically, Voxel's own EV-to-EBIT has ranged from 5.36 to 22.32 over the past decade. While the company's 10-year median is 10.02 vs. the industry median of 24.21, Voxel has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.21, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voxel's current EV-to-EBIT of 10.73 is 55.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Voxel and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voxel's current EV-to-EBIT is 10.73, which is near median its own 10-year median of 10.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voxel stock overvalued right now?
Voxel (LTS:0QDB) has a current EV-to-EBIT of 10.73. The stock's GF Value™ is zł110.70, compared to a current price of zł109.00 — trading 1.5% below its estimated fair value. The current EV-to-EBIT is 10.73, which is near median its 10-year median of 10.02 and 55.7% below the Medical Diagnostics & Research industry median of 24.21. Voxel's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Voxel (LTS:0QDB), the current EV-to-EBIT is 10.73 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voxel (LTS:0QDB) Overvalued in 2026?
Based on GuruFocus' analysis, Voxel stock appears to be undervalued.
The current stock price of zł109.00 is trading 1.5% below its estimated GF Value™ of zł110.70.
Key valuation signals for LTS:0QDB:
EV-to-EBIT: 10.73 (near median its 10-year median of 10.02)
GF Value™: zł110.70 vs. price of zł109.00 (1.5% below fair value)
Industry Position: 55.7% below the Medical Diagnostics & Research median (#22 of 106)
No single metric tells the full story. See the LTS:0QDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voxel SA is a network of diagnostic imaging laboratories created for patients and to increase access to high-quality tests. The company operates diagnostic imaging centers and laboratories and provides several services such as magnetic resonance imaging, computed tomography and positron emission tomography. It has 33 specialised laboratories in 21 cities throughout Poland.
95GF Score
Get the complete analysis for LTS:0QDB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QDB has been successfully added to your 
